STAT+: An accidental data release by Roche boosts some hopes for anti-TIGIT cancer immunotherapies
The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target…
Category: STAT+
STAT+: Apellis safety probe of eye disease drug identifies injection needle as possible cause of severe side effect
Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of…
STAT+: Former Pear Therapeutics executives start new VC firm, with biotech veteran Bob Langer as adviser
Executives from the shuttered digital health company Pear Therapeutics are launching a new VC firm,…
STAT+: FDA approves Pfizer’s RSV vaccine for newborns; Boehringer sues over IRA
Good morning, one and all. Damian Garde here, filling in for Ed Silverman once more…
STAT+: FDA advisory panel to debate contentious data on Medtronic’s high blood pressure device
An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate…
STAT+: Eli Lilly CEO donates big to Mike Pence presidential super PAC
WASHINGTON — David Ricks, who leads Eli Lilly, made a major early donation to a…
STAT+: Intellia plays down concerns about accidental germline transmission in CRISPR trial
Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in…
STAT+: Pharmalittle: Regeneron wins a delayed approval; Bristol, J&J likely to face pricing negotiation
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on yet another dog…
STAT+: As the obesity drug market grows, digital health companies juggle patients and payers
To much of the public, the promise of telehealth is all about convenience — get…
STAT+: Pharmalittle: Weight loss drugs cost much more in the U.S.; PBMs win a key victory over an Oklahoma law
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ViiV Healthcare and Doctors Without Borders tussle over contract terms for an HIV drug
A feud has erupted between ViiV Healthcare and Doctors Without Borders over a deal to…
STAT+: Blue Shield of California overhauls drug pricing operation — by adding more vendors
Blue Shield of California, a health insurance company that covers almost 5 million people, is…
STAT+: U.S. appeals court strike down key provisions in Oklahoma law that regulates PBMs
A U.S. appeals court struck down key parts of an Oklahoma law designed to regulate…
.jpg)
STAT+: Pharmalittle: U.S. appeals court upholds limits to abortion pill; ‘knock-off’ Ozempic thrives on ‘bogus’ website
Top of the morning to you. And a steamy one, it is. In fact, there…
.jpg)
STAT+: South Africa ordered to disclose contracts with Pfizer, J&J, and other Covid-19 vaccine makers
A South African court ruled the government must disclose contracts signed with pharmaceutical companies for…
STAT+: ActiGraph executives on why getting digital endpoints approved for drug trials matters
As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become…
STAT+: Health care CEOs hauled in $4 billion last year as inflation pinched workers, analysis shows
The health care industry didn’t just provide a safe haven for jittery stock investors in…
STAT+: FDA approves first treatment for ultra-rare bone disease
U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people…
STAT+: Schizophrenia gene found to be linked to energy dysfunction in brain cells
The heritable nature of schizophrenia has been known for about a century. But researchers are…
The latest recall of Philips ventilators reveals one death, two injuries
In March, Philips recalled more than 73,000 ventilators that absorbed dust and dirt into breathing…
STAT+: In a rare move, FDA threatens to fine a company for failing to report clinical trial results
For only the fifth time, the U.S. Food and Drug Administration recently threatened to fine…
STAT+: Pharmalittle: Chinese drugmakers develop copycat weight loss drugs; SEC eyes supplier of research monkeys
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: With an age cutoff for a new gene therapy, families and doctors scramble to treat kids before their 6th birthday
In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had…
STAT+: FDA warns AstraZeneca over misleading promotional materials for a COPD drug
The U.S. Food and Drug Administration scolded AstraZeneca for making misleading claims about the effectiveness…
STAT+: SEC wants to know if key supplier of research monkeys bribed foreign officials
A U.S. government probe into a monkey-smuggling operation emanating from Cambodia has gone in a…
STAT+: Pharmalittle: Amazon Pharmacy offers insulin discounts; DOJ blasts industry attempt to delay Medicare drug-price talks
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: BMS, looking to build a market for a heart drug, turns to a Viz.ai algorithm to detect disease
As Bristol Myers Squibb works to build its treatment for a heart condition that can…
STAT+: From drug shortages to high prices, U.S. system’s shortcomings have deep roots
American medicine is a tragic paradox. An example: Cancer patients are likely dying as a…
STAT+: Not-for-profit CommonSpirit Health paid its CEO $35 million in 2021
CommonSpirit Health, the massive not-for-profit health system formed through a 2019 merger, paid its former…
STAT+: Pharmalittle: White House drug-shortage panel is MIA with lawmakers; Ultragenyx sued by Lacks family
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment
Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that…
STAT+: In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need
Emma Albee knows the experimental drug she takes is not a cure. It won’t allow…
STAT+: After Optum Health’s lowest profit margin in a decade, UnitedHealth makes changes
Just weeks after the division of UnitedHealth Group that provides care to patients posted its…
STAT+: Hospitals are dialing back on venture capital investing
Hospitals once dove headfirst into venture capital with splashy headlines and attention-grabbing numbers. Now, in…
STAT+: More hospital pharmacists are rationing drugs due to increasing shortages
Nearly every hospital pharmacy across the U.S. is experiencing shortages of prescription drugs. And the…
STAT+: Pharmalittle: Supreme Court halts Purdue bankruptcy plan; what to know about compounded obesity drugs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: EPA fines Roche’s Genentech unit for hazardous waste violations
Following an extensive inspection, the U.S. Environmental Protection Agency fined Genentech more than $158,000 for…
STAT+: AdventHealth sues MultiPlan, alleging a ‘cartel’ that underpays out-of-network medical claims
AdventHealth, a large religious-affiliated hospital system, has sued MultiPlan, alleging the company has worked with…
STAT+: What to know about concerns raised about compounded versions of Novo Nordisk’s Wegovy
As demand for Ozempic and Wegovy surges, a little noticed warning about the medicines was…
STAT+: A yogurt drink instead of a colonoscopy? Study uses engineered bacteria to detect cancer
Dan Worthley, a gastroenterologist and cancer scientist at Colonoscopy Clinic in Brisbane, Australia, does thousands…
STAT+: Pharmalittle: Genentech weighs delaying cancer therapy after drug pricing law; Novo continues to restrict supplies of low-dose Wegovy
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials
Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results…
STAT+: Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach
Fresh off of the news that its drug Wegovy may not just help people lose…
STAT+: Telehealth companies are driving a large share of weight loss drug prescriptions, claims data suggest
As a new class of obesity medications has soared in popularity, so have the online…
STAT+: Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental…
Opinion: STAT+: What Mark Cuban gets wrong about prescription drugs
Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently…
STAT+: Novo Nordisk celebrates landmark Wegovy study, even as supply issues persist
The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives…
STAT+: DNA-sequencing giant Illumina slashes 2023 revenue projections yet again
SAN DIEGO — After starting off the year by lowering its 2023 revenue projections, San…
STAT+: Pharmalittle: Wegovy heart study has docs seeing new possibilities; drugmakers file more ‘continuation’ patents that sideline generic rivals
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Opinion: STAT+: One way to create resilient drug supply chains: incentivize predictive models
My first exposure to pharmaceutical shortages happened in 2017 as a new-to-practice nurse working on…